Jack Lief Named Chairman of ADVENTRX Pharmaceuticals
June 12 2007 - 7:00AM
PR Newswire (US)
SAN DIEGO, June 12 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases,
today announced that Jack Lief, president and chief executive
officer, and a founder and director of Arena Pharmaceuticals, Inc.
(NASDAQ:ARNA), was named Chairman of ADVENTRX. "I'm very pleased to
accept the position as Chairman of ADVENTRX. I hope my knowledge
and experience continues to prove valuable as ADVENTRX progresses
with its Phase 3 clinical trial of ANX-510 and as the company
continues to move other product candidates into the clinic that
also hold significant potential to provide patients better
treatment options," commented Jack Lief, president and CEO of
Arena. Mr. Lief joined ADVENTRX's board of directors in September
2006 and also serves on the board of directors of Accumetrics,
Inc., a developer and marketer of diagnostic tests, ReqMed Company,
Ltd., a provider of partnering opportunities, R&D strategies
and bio-venture funding, and TaiGen Biotechnology Co., Ltd., a
biotechnology company. In addition, Mr. Lief is an executive board
member for BIOCOM, a life science industry association representing
more than 450 member companies in San Diego and Southern
California, and from March 2005 to March 2006, served as chairman
of BIOCOM. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals
is a biopharmaceutical research and development company focused on
commercializing proprietary product candidates for the treatment of
cancer and infectious diseases. The Company seeks to improve the
performance and safety of existing treatments by addressing
significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can
be found on the Company's web site at http://www.adventrx.com/.
Forward Looking Statement ADVENTRX cautions you that statements
included in this press release that are not a description of
historical facts are forward-looking statements that involve risks
and assumptions that, if they materialize or do not prove to be
accurate, could cause ADVENTRX's results to differ materially from
historical results or those expressed or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to: the risk that directors will undertake
projects that divert their respective attention from ADVENTRX
matters, or that may pose a conflict of interest with ADVENTRX;
ADVENTRX's ability to raise sufficient capital to fund the projects
necessary to meet its anticipated or stated goals; the ability to
timely enroll subjects in ADVENTRX's current and anticipated
clinical trials; the results of pending clinical trials for
CoFactor(R) or ADVENTRX's other product candidates; the potential
for CoFactor(R) and ADVENTRX's other product candidates to receive
regulatory approval for one or more indications, and the uncertain
process of seeking regulatory approval; other difficulties or
delays in developing, testing, manufacturing and marketing and
obtaining regulatory approval for CoFactor(R) and ADVENTRX's other
product candidates; unexpected adverse side effects or inadequate
therapeutic efficacy of CoFactor(R) or ADVENTRX's other products;
and other risks and uncertainties more fully described in
ADVENTRX's press releases and public filings with the Securities
and Exchange Commission. ADVENTRX's public filings with the
Securities and Exchange Commission are available at
http://www.sec.gov/. ADVENTRX does not intend to update any
forward- looking statement, including as set forth in this press
release, to reflect events or circumstances arising after the date
on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc.
CONTACT: investors, Ioana C. Hone of ADVENTRX, +1-858-552-0866 Web
site: http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024